Systemic and Ocular Predictive Factors in the Treatment of Diabetic Macular Edema with Bevacizumab.

Background and Objectives: This study aimed to explore peripheral blood and OCT risk biomarkers that may modify the anatomical and functional response to intravitreal bevacizumab (IVB) treatment in diabetic macular edema (DME). Materials and Methods: The study included patients with non-proliferative diabetic retinopathy (NDR) who had not previously undergone laser photocoagulation or IVB. Data on demographics, hemogram, and biochemistry within one month before treatment were collected. Best corrected visual acuity (BCVA), intraocular pressure (IOP), and spectral-domain OCT (SD-OCT) measurements were recorded before and after three monthly IVB injections. OCT parameters included central macular thickness (CMT), inner and outer retinal thickness (IRT, ORT), ganglion cell layer thickness (GCT), and central choroidal thickness (CCT). Results: The study analyzed 48 eyes. Significant improvements were seen in BCVA (logMAR 0.44 to 0.18), while IOP increased slightly (15 to 17.5 mmHg). There were notable reductions in CMT, GCT, and IRT. Anatomical success (83.3%) was associated in univariate analysis with greater OCT improvement and higher white blood cell count (WBC) levels (p < 0.05). Central macular thickness decreased by 27% (from 427 to 312 μm), and visual acuity improved from 0.44 to 0.18 logMAR. In logistic regression analysis, factors associated with functional success (75%) included higher blood urea nitrogen (BUN) levels [OR 1.11 (95% CI: 1.03-1.21), p = 0.008], lower low-density lipoprotein (LDL) levels (p = 0.013), and lower baseline intraocular pressure (IOP) (p = 0.013). Conclusions: Intravitreal bevacizumab is effective in early diabetic macular edema. Elevated BUN and lower LDL levels may be associated with a favorable functional response to treatment.

• Publication year

  2026

• Venue

  Medicina

• Publication date

  2026-01-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/medicina62020283PMID 41752682PMCID PMC12942624
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Conbercept Treatment for Heart‐Shaped Vascular Intertwined Nets in Macular Neovascularization: Anti‐VEGF Drug Therapy Strategy Based on Vascular Geometry Diagnosed by OCTA

  2025cited by this paper
• Influence of Intravitreal Therapy on Choroidal Thickness in Patients with Diabetic Macular Edema

  2023cited by this paper
• Factors Affecting Intensive Aflibercept Treatment Response in Diabetic Macular Edema: A Real-World Study

  2023cited by this paper
• The impact of laboratory findings and optical coherence tomography biomarkers on response to intravitreal anti-VEGF treatment in patients with retinal vein occlusion

  2022cited by this paper
• Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology.

  2021cited by this paper
• Protective role of vitamin D against oxidative stress in diabetic retinopathy

  2021cited by this paper
• Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema

  2020cited by this paper
• SYSTEMIC FACTORS AND EARLY TREATMENT RESPONSE TO INTRAVITREAL INJECTION FOR DIABETIC MACULAR EDEMA

  2020cited by this paper
• Correlation of Lipid Profile with Duration of Diabetes and HbA1c Levels in Type 2 Diabetes Mellitus Patients: A Descriptive Cross-sectional Study

  2020cited by this paper
• Correlation of retinal layer changes with vision gain in diabetic macular edema during conbercept treatment

  2019cited by this paper
• Prevalence of anemia among type 2 diabetes mellitus patients in correlation with HbA1c levels a prospective study

  2018cited by this paper
• Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy

  2018cited by this paper
• Diabetic Retinopathy: Pathophysiology and Treatments

  2018cited by this paper
• CORRELATION OF OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI WITH VISUAL OUTCOMES IN DIFFERENT PATTERNS OF DIABETIC MACULAR EDEMA

  2016cited by this paper
• The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema.

  2016cited by this paper
• The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness

  2016cited by this paper
• One-Year Progression of Diabetic Subclinical Macular Edema in Eyes with Mild Nonproliferative Diabetic Retinopathy: Location of the Increase in Retinal Thickness

  2015cited by this paper
• Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab.

  2015cited by this paper
• A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study.

  2014cited by this paper
• Retinal Layers Changes in Human Preclinical and Early Clinical Diabetic Retinopathy Support Early Retinal Neuronal and Müller Cells Alterations

  2013cited by this paper
• Serum lipid profile in diabetic macular edema.

  2009cited by this paper
• Foveal ganglion cell layer damage in ischemic diabetic maculopathy: correlation of optical coherence tomographic and anatomic changes.

  2009cited by this paper
• The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes.

  2008cited by this paper
• Management of diabetic retinopathy: a systematic review.

  2007cited by this paper
• INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR PERSISTENT DIFFUSE DIABETIC MACULAR EDEMA

  2006cited by this paper
• Diabetes-induced dysfunction of retinal Müller cells.

  2002cited by this paper
• Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin.

  1998cited by this paper

• No citing papers are available for this paper.